Sangon Biotech: difference between revisions
Diff·revision 10 → 11·09:08, 9 Apr 2025
Difference between revision 10 and revision 11 of Sangon Biotech. 7 lines changed; the page grew by 144 bytes.
| Revision 10 — 21:46, 19 Mar 2025 ColdChainCleo (talk) clarify that a registered business scope is a licensing fact, not a quality assurance 6,767 bytes +822 | Revision 11 — 09:08, 9 Apr 2025 UnderfillUna (talk) expand §Notability and coverage 6,911 bytes +144 | ||
|---|---|---|---|
| 61 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 61 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |
| 62 | 62 | ||
| + | 63 | == See also == | |
| + | 64 | * [[Certificate of analysis]] | |
| + | 65 | * [[Third-party testing]] | |
| + | 66 | * [[Area percent purity]] | |
| + | 67 | * [[Peptide content]] | |
| + | 68 | * [[Research use only]] | |
| + | 69 | ||
| 63 | {{DEFAULTSORT:Sangon Biotech}} | 70 | {{DEFAULTSORT:Sangon Biotech}} |
| 64 | [[Category:Peptide suppliers]] | 71 | [[Category:Peptide suppliers]] |